EnlivexEnlivex is a publicly traded company (Nasdaq: ENLV) operating with two distinct but connected components. The first is its clinical-stage immunotherapy asset, Allocetra™, which targets age-related knee osteoarthritis. The therapy is designed to reprogram macrophages—immune cells involved in inflammation—with the goal of restoring mobility and function in aging populations. Phase II clinical data reported a 72% reduction in pain and a 109% improvement in function across more than 250 treated patients.The second component is a treasury model. Rather than holding cash or passive token reserves, Enlivex anchors its treasury in Rain, a decentralized prediction markets protocol on Arbitrum. The company’s treasury exposure is tied to Rain protocol activity, with a fee-linked buyback mechanism connected to network usage. This structure is intended to create a link between the company’s financial reserves and the economic activity of the prediction markets infrastructure, while reducing reliance on repeated equity dilution for capital.